🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522782-30-00
Ongoing Phase I

A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults

2025-522782-30-00 · tracked via the Priya Life Science EU tracker
Sponsor
UCB Biopharma
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
16/03/2026
Enrollment target
293
Sites
Croatia, Poland, Germany, Czechia, Slovakia, Bulgaria

Condition studied

CCI

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522782-30-00 on CTIS ↗ ← All trials in the EU